Shanyu Liu

机构：Gilead Sciences (United States) · ORCID：0000-0002-5787-2251

发表论文 43 篇 · 总被引 1023 次 · h-index 10

代表论文

• Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial (2022 · The Lancet HIV · 被引 107)
• Using dual-task gait to recognize Alzheimer’s disease and mild cognitive impairment: a cross-sectional study (2023 · Frontiers in Human Neuroscience · 被引 13)
• Optimization of electrical stimulation for the treatment of lower limb dysfunction after stroke: A systematic review and Bayesian network meta-analysis of randomized controlled trials (2023 · PLoS ONE · 被引 12)
• Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 (2025 · Annals of Internal Medicine · 被引 9)
• Association between chronic kidney disease and sarcopenia and emerging treatment strategies (2025 · Frontiers in Nutrition · 被引 7)
• 577. Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir (2025 · Open Forum Infectious Diseases · 被引 6)